Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196599 | 0.85 | KMT2A (1.00) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL954146 | 0.85 | KMT2A (0.76) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL8315301 | 0.85 | KMT2A (1.00) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL954303 | 0.83 | KMT2A (0.73) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL24655998 | 0.81 | MAPK1 (0.74) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL19675464 | 0.81 | KMT2A (0.69) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL12789839 | 0.81 | KMT2A (0.69) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL11267017 | 0.81 | KMT2A (0.69) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL17321376 | 0.81 | KMT2A (0.69) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL26054712 | 0.81 | KMT2A (0.74) | KMT2AALDH1A1KDM4EGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242565-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF IN THE PREVENTION OR THERAPY OF DISEASES | Samsara Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4653432-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF IN THE PREVENTION OR THERAPY OF DISEASES | Samsara Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-1682549-B1 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR INC (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-7148353-B2 | Imidazo[1,2-a] pyridine anxiolytics | SEPRACOR INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1682549-A2 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | Sepracor Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050171144-A1 | Imidazo[1,2-a] pyridine anxiolytics | SEPRACOR INC. (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005044818-A2 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | CNR1, CNR2, GABRA5 | KMT2A 345/4885ALDH1A1 300/4885KDM4E 995/4885 |
| US-20050171144-A1 | Imidazo[1,2-a] pyridine anxiolytics | CNR1, CNR2, GABRA5 | KMT2A 345/4885ALDH1A1 300/4885KDM4E 995/4885 |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | MTNR1B, ADORA2B, ADRA2B | KMT2A 181/4885ALDH1A1 321/4885KDM4E 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.